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Less than 2% of patients diagnosed with cancer participate in a clinical trial in the United States (1). 
Gynecologic oncology patients do not appear to participate in trials with any more frequently than 
other cancer types. While gains in progression free survival have continued to improve overall life 
span for women with advanced gynecologic cancers, more cures have not been realized. Clinical 
trials, defined by the National Institute of Health as “a research study in which one or more human 
subjects are prospectively assigned to one or more interventions to evaluate the effects of those 
interventions on health-related biomedical or behavioral outcomes” (2), are the primary focus for 
enrollment of most patients with an active malignancy. Clinical research studies such as tissue banks 
and longitudinal cohort studies provide invaluable data for researchers but require a consenting 
population and may be overlooked when the focus is on therapeutic intent. Lack of accrual to clinical 
trials leads to early closure of studies and a waste of critical resources as well as extended periods of 
enrollment, which can hinder the ability to interpret the results. Stensland et al. reported that 1 in 4 
cancer clinical trials were stopped early with 1 in 10 being stopped for poor accrual (3). A panel of 
experts convened by the NCI and ASCO to discuss barriers to clinical trial enrollment in 2013 (4) 
cited barriers in three areas as most significant: (1) patient/community, (2) physician/provider level, 
and (3) site/organizational. Physician/provider level barriers include willingness to refer a patient 
for study, lack of knowledge about available clinical trials, and concern regarding a patient’s ability 
to participate (4–6). Patient/community barriers have been noted to include being unaware of trial 
opportunities and complexity and stringency of the protocol (7).
But really, in this time of internet and social media, of immediate and total access to seemingly 
endless information, why are adult patients not enrolling on clinical trials? A large single institution 
review of clinical trial enrollment noted a dramatic difference in the proportion of pediatric cancer 
patients enrolled in clinical trials compared to adult (22 vs. 6%) (8). Is this because parents of children 
with cancer and young adults with cancer are so much better at searching the internet for clinical 
trial opportunities? Unlikely, this high rate of participation in the pediatric population preceded the 
internet age. I believe there are two vital differences between the adult and pediatric cancer com-
munities. First, centralization of treatment in pediatric cancer results in high volume centers. The 
rarity of pediatric cancer forced pediatric oncologists to band together in universities and research 
centers. The vast majority of children and young adults are treated in these centers today. Data from 
several areas suggest that treatment in high volume centers results in improved pediatric oncology 
outcomes (8, 9). Still, most pediatric cancers are exceptionally rare. Even at high volume centers, 
collaboration with other sites must be done to gather enough similar cases for research.
Second, and perhaps most importantly, there is a pervasive culture in pediatric oncology that 
“clinical trials are standard practice in cancer treatment for children, adolescents, and young adults” 
(https://www.childrensoncologygroup.org/index.php/what-is-a-clinical-trial). The pediatric oncol-
ogy community has remained faithful to the charge that cure is the goal (10). In addition, the research 
structure embraces that the cancers in this space are inherently rare and as such designed studies that 
use the available patient volume. These elements seem to combine to provide a complete package 
of physician motivation, patient engagement, and available studies for the vast majority of patients 
despite the low numbers.
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In gynecologic oncology, there are no data to suggest that 
female gynecologic cancer patients participate in clinical trials 
at a higher rate. However, a recent large retrospective study by 
Cliby et  al. suggests that treatment for ovarian cancer at high 
volume centers improves outcomes (11). The authors of this 
study suggest that a national effort be made to provide access to 
women to centers with expertise in ovarian cancer. It remains 
to be seen if these data will move patients from community set-
tings into centers where participation in clinical trials is more 
common.
The National Comprehensive Cancer Network states on their 
website that “without clinical trials, cancer care can’t improve.” 
This group compiles clinical practice guidelines from the data 
produced by clinical trials to help guide the care for patients 
treated off study. Access to this resource is simple and available to 
both patients and providers. It is updated regularly and carefully 
curated.
This is in sharp contrast to information about open clinical 
trials. The main resource for clinical trials information is the 
national registry of clinical trials, which is available online at 
www.clinicaltrials.gov. The goal of the registry was to require 
the registration of all clinical trials in the US and to provide a 
resource for clinicians and patients to find open studies. The 
site is searchable by location and disease but is often woefully 
out of date. Studies that have closed months ago are often still 
listed as actively recruiting, studies that have published data are 
not listed as published, and studies that are open will often have 
incorrect listings of site information. This lack of timely and cor-
rect information results in the inability for interested patients and 
clinicians to find open and appropriate trials.
The barriers for women with cancer to participate in clinical 
trials are numerous but they are not insurmountable. Dramatic 
and sweeping cultural change is necessary to bring about rates of 
adult enrollment that rival the pediatric population. A profound 
commitment to the provision of timely data to the national clinical 
trials registry by sponsors and the timely curating of the website 
is required for better clinical trial information. A commitment 
to providing access to high volume centers with experience in 
gynecologic cancer is required for improving outcomes with the 
current available strategies. Lastly, physicians and patients need 
to fully commit themselves to a belief that clinical trial participa-
tion can really bring about better treatments and better drugs and 
most importantly, better lives.
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